122 results about "Phosphocholine" patented technology

The invention belongs to the field of nutrient substance research, and particularly relates to a nutritional composition beneficial to improvement of neural behaviors and cognition. The nutritional composition provided by the invention comprises necessary active ingredients shown in the following (i) and (ii): (i) lactose-N-neotetraose, (ii) 1, 2-diacyl-sn-glycerol-3-phosphorylcholine, and (iii) 1, 2-diacyl-sn-glycerol-3-phosphorylcholine. The nutritional composition comprises lactose-N-neotetraose and 1, 2-diacyl-sn-glycerol-3-phosphorylcholine, and in the nutritional composition, the mass ratio of the lactose-N-neotetraose to the 1, 2-diacyl-sn-glycerol-3-phosphorylcholine is 1: (0.010-2.0). The lactose-N-neotetraose and the 1, 2-diacyl-sn-glycerol-3-phosphorylcholine can achieve a synergistic effect to improve filial generation repeated engraving behaviors caused by maternal immune activation, decrease of social behavior ability and decrease of anxiety state and memory and recognition ability.

The invention belongs to the technical field of bioengineering, and particularly relates to a phosphorylcholine cytidyltransferase mutant and application thereof. On the basis of phosphorylcholine cytidyltransferase MsCCT001, any one or more of N194D, K91E, G98S, S148A and C156V are mutated respectively, a series of phosphorylcholine cytidyltransferase mutants are obtained through screening, and the obtained mutants have the advantages that in the reaction of catalyzing phosphorylcholine and cytidine triphosphate to generate citicoline, the yield of the obtained mutants is increased, and the yield of the obtained mutants is increased. The catalytic efficiency of the compound is 1.90-2.41 times that of initial phosphorylcholine cytidyltransferase, and a biological enzyme preparation with higher catalytic capacity is provided for preparing citicoline by a biological conversion method.

The object of the present invention is to provide a novel ascorbic acid derivative with excellent stability, and its applications. [Solution] A compound (compound of general formula (1) below) is used, in which a phosphocholine group is introduced to the hydroxyl group at the 2 position of ascorbic acid via a phosphate ester bond. The ascorbic acid derivative of the present invention has excellent whitening and antioxidant properties, and is also highly stable. Therefore, the ascorbic acid derivative of the present invention can be preferably used as an active ingredient in cosmetics and topical skin preparations. TIFF2026055124000012.tif39101

The invention belongs to the technical field of organic synthesis, and relates to a preparation method of N-palmitoyl-O-phosphorylcholine serine and a deuterated substance thereof. The N-palmitoyl-O-phosphorylcholine serine and the deuterated substance thereof are obtained by taking L-serine methyl ester hydrochloride and palmitic acid as raw materials through amidation reaction, phosphate esterification reaction, quaternization reaction, oxidation reaction, reduction reaction and the like. The invention provides an approach for industrial production of the N-palmitoyl-O-phosphorylcholine serine and the deuterated substance thereof, and is very important for standardization of the detection method of the N-palmitoyl-O-phosphorylcholine serine.

The present invention relates to an ophthalmological composition, comprising at least one nicotinic acetylcholine receptor (nAChR) modulator, in particular varenicline, mecamylamine and derivatives, and / or at least one substance of the endogenous Kennedy metabolic pathways, as well as salts and derivatives or pharmaceutically acceptable salts of these substances, and choline-containing phospholipids, salts and derivatives of these substances. From these groups, particular preference is given to choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (for example lecithin having a phosphatidylcholine content ≥ 80 wt.%, for example soy lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-α-glycerylphosphorylcholine, phosphatidylcholine, and phosphatidylethanolamine.

The present disclosure provides polypeptides that specifically bind to phosphocholine (PC). Also provided are pharmaceutical compositions comprising these polypeptides, nucleic acids encoding these polypeptides, expression vectors and host cells for making these polypeptides, and methods of treating a subject using these polypeptides.

The invention discloses a polymer hydrophilic coating in the field of biomedical materials, a preparation method of the polymer hydrophilic coating and application of the polymer hydrophilic coating in medical catheters. The coating achieves excellent performance through the synergistic effect of two newly designed modified compounds. Wherein the phosphorylcholine silane functionalized polyethyleneimine is used as a matrix material and provides hydrophilicity and anticoagulant activity; and the nano silicon dioxide anchored polyhexamethylene biguanide is used as a functional filler, so that the coating is endowed with antibacterial property and mechanical enhancement. During preparation, all the components are sequentially dissolved in water to form a uniform solution, transparent sol is formed through silane hydrolysis, then the pretreated guide pipe is subjected to dip coating, and a final product is obtained through preheating, ultraviolet light curing and heat curing treatment. The coating obviously reduces the surface friction coefficient, has lasting hydrophilicity, efficient antibacterial property and excellent blood compatibility, is firmly combined with a base material, and is particularly suitable for surface functional modification of various interventional medical catheters.

The present invention relates to ophthalmic compositions comprising at least one substance of at least one nicotinic acetylcholine receptor (nAChR) modulator, in particular varenicline, megamine and derivatives thereof, and / or the endogenous Kennedy metabolic pathway, as well as salts and derivatives or pharmaceutically acceptable salts of these substances, and choline-containing phospholipids, salts and derivatives of these substances. From these groups, particularly preferred are choline, phosphocholine, CDP-choline (citicoline), phosphatidylcholine (e.g. Lecithin having a phosphatidylcholine content of > = 80% by weight, e.g. Soybean lecithin), ethanolamine, phosphoethanolamine, CDP-ethanolamine, phosphatidylethanolamine, L-alpha-glycerophosphorylcholine, phosphatidylcholine, phosphatidylethanolamine.

The invention relates to a magnesium- aluminium layered double hydroxide (Mg-Al LDH) based filler product comprising boron and functionalised with phosphocholine chloride calcium salt tetrahydrate (PC), the synthesis method of this filler product, and obtaining a new material by preparing a composite material of this filler product, which has antibacterial activity, with a thermoplastic polymer or thermosetting polymer. In the production of the composite material that is the subject of the invention, as the polymer, preferably unsaturated polyester resin (DPes) is used. The composite material comprising the filler product of the invention has the feature of preventing bacterial adhesion / biofilm formation. Said material has the potential to be used for various applications, including medical devices, industrial processes, food production, storage and sales areas, food contact surfaces, areas requiring cleaning and hygiene, and different surface materials.

The invention belongs to the technical field of microorganisms, and particularly relates to phospholipid from extracellular vesicles of phytobacterium plantarum and application of the phospholipid. Specifically, the plant lactobacillus extracellular vesicles can restore the skin barrier; the expression of proinflammatory factors in a cell inflammation model can be reduced, and a relatively good anti-inflammatory effect is achieved. Through metabolome analysis, it is found that effective substances having effects on skin barrier injury comprise phospholipid 1-palmitoyl-sn-glycerol-3-phosphorylcholine (PC, 16: 0 / 0: 0); experiments prove that PC (16: 0 / 0: 0) can regulate the expression of skin barrier related genes in the SDS-induced damaged cell model; and the expression of skin inflammation-related genes in the SDS-induced damaged cell model is regulated, so that the SDS-induced SDS-induced damaged cell model can be used as a medicine for treating skin barrier injury.

The invention discloses application of a marker to preparation of a kit for diagnosing chronic obstructive pulmonary diseases. According to the application disclosed by the invention, the accuracy of diagnosing the chronic obstructive pulmonary disease by using (R)-3-hydroxytetradecanoic acid alone or in combination with the azelayl platelet activating factor is relatively high; on the basis of combination of (R)-3-hydroxytetradecanoic acid and an azelayl platelet activating factor, the compound is prepared. The compound can be further combined with one or two of 1-hexadecyl-2-(5-oxovaleryl)-sn-glycerol-3-phosphorylcholine, 1-O-hexadecyl-SN-glycerol-3-choline phosphoric acid, lauroyl-L-carnitine and beta-acetyl-gamma-O-alkyl-L-alpha-phosphatidylcholine to be used for diagnosing the chronic obstructive pulmonary disease. Therefore, a diagnostic kit for diagnosing the chronic obstructive pulmonary disease can be prepared on the basis of the scheme, and the kit contains a compound standard substance corresponding to the scheme and can also contain an internal standard compound for mass spectrum quantitative analysis.

The present invention provides therapeutic and / or prophylactic treatments against leishmaniasis in non-human mammals in need of such treatment, said treatments comprising administering oleyl phosphocholine to said non-human mammal. The invention also relates to veterinary (pharmaceutical) compositions adapted, suitable and / or intended for use in these treatments.

The present invention belongs to the field of pharmaceutical technology and discloses the use of 1-Oleoyl-2-palmitoy-sn-glycero-3-phosphocholine (OPPC) combined with γ-Linolenic acid in the preparation of a medicament for treating autoimmune liver disease (ALD). The medicament for treating autoimmune liver disease according to the present invention comprises OPPC and / or γ-Linolenic acid, as well as derivatives of OPPC and / or γ-Linolenic acid. By administering the medicament of the present invention to treat MRL / MpJ-Fas<supgt;lpr< / supgt; (MRL / lpr) mice, the plasma metabolic level and liver function of MRL / lpr mice can be improved, providing a new direction for the clinical treatment of autoimmune liver disease.

The invention discloses a dry powder drag reducer for fracturing fluid and a preparation method of the dry powder drag reducer, and relates to the technical field of fracturing fluid additives for gas field exploitation. The invention relates to an anionic polymer, which is prepared from the following raw materials in parts by weight through copolymerization: 25 to 35 parts of N-acryloyl morpholine, 5 to 8 parts of 2-methacryloyloxyethyl phosphorylcholine, 3 to 5 parts of 2-vinyl-4, 5-dihydrooxazole, 40 to 50 parts of anionic monomer, 0.1 to 0.5 part of initiator, 0.05 to 0.2 part of chain transfer agent and 0.5 to 2 parts of dispersing agent. The drag reducer is remarkable in drag reduction effect, excellent in temperature resistance and salt resistance and rapid in dissolution.

This invention relates to the field of building materials technology, and particularly to a viscosity-reducing polycarboxylate superplasticizer and its preparation method. The viscosity-reducing polycarboxylate superplasticizer uses polyethylene glycol dicyclopentenyl ether methacrylate as the macromonomer, combined with 2-methacryloyloxyethyl phosphocholine, 4-vinylphenylboronic acid, and polyethylene glycol phenyl ether methacrylate as small monomers, prepared via free radical polymerization. Finally, it undergoes freeze-drying and grinding to obtain the target powder product. When the prepared superplasticizer is added to concrete mixtures, it swells and unfolds into a comb-shaped polymer under mechanical stirring and alkaline conditions. Through PEG long side-chain lubrication and steric hindrance, the regulation of surface tension / interfacial energy by phosphocholine groups, and the selective adsorption of borate groups, the initial viscosity is significantly reduced, the viscosity increase over time is controlled, and segregation and bleeding are effectively suppressed, making it suitable for various cementitious systems.

Disclosed are the use of a metabolic marker in the preparation of a product for monitoring PB neurotoxicity and a product thereof, which can be used for the early diagnosis of PB neurotoxicity with high sensitivity, rapidity, convenience, and accurate and reliable results. The metabolic markers include LysoPE 20:4 / 0:0, creatine, SM d18:1 / 24:0, SM d18:0 / 24:1, LysoPC 18:0, palmitoyl sphingomyelin, phosphocholine, PC 14:0 / 22:1, creatinine, PC 18:3 / 16:0, SM d18:1 / 16:0, sphingosine, choline, LysoPC 18:1, L-carnitine, palmitic acid, PC 18:0 / 20:4, 3-hydroxy-2-octylglutaric acid, L-acetylcarnitine, LysoPC 20:4, LysoPC 16:0, and PC 20:1 / 14:1.

The application discloses a kind of medical high-barrier packaging film and preparation method, it is related to packaging film field.The application is when preparing medical high-barrier packaging film, mica sheet is grafted [3-(trimethoxysilyl) propyl] succinic anhydride after with glycerol phosphocholine, maleic anhydride reaction and obtain modified mica sheet;1.4-pyrazine dimethylaldehyde and 4-amino-3-mercapto benzoic acid are reacted and copolymer is obtained;Then caprolactam, 1,4-diamino-2,5-divinyl benzene and copolymer are reacted and polyamide particle is obtained;Polyamide particle and modified mica sheet are reacted and medical high-barrier packaging film is obtained.The medical high-barrier packaging film prepared by the application has excellent barrier property, antifouling property, antibacterial property and mechanical property.

The present application relates to a kind of cytidine choline dextrohydrotalcid derivatives and its preparation method and application, belong to biological medicine technical field.The present application is aimed at solving the technical problems of low blood-brain barrier penetration rate and limited treatment effect of existing edaravone dextrohydrotalcid compound preparation.The present application prepares a dextrohydrotalcid derivative (C-B) with boronic acid structure, then it is compounded with cytidine choline in specific pH buffer system, and forms cytidine choline dextrohydrotalcid derivative (C-D-B).The present application can effectively improve the efficiency of drug crossing blood-brain barrier by using the dynamic covalent characteristics of boronic ester bond and free radical responsiveness.The experimental results show that, compared with existing combination drug, the derivative of the present application can significantly reduce the infarction area of cerebral ischemia model animal, reduce cell damage and active oxygen level, and promote vascular regeneration, and show better treatment effect on ischemic brain injury.

The invention belongs to the technical field of organic synthesis, and particularly relates to a polymeric organic base and application of the polymeric organic base in catalytic preparation of a phosphatidylcholine compound. The polymeric organic base disclosed by the invention is a diblock polymer formed by polymerizing a biimidazole guanidine organic tertiary phosphine chain segment and a functional phosphorylcholine chain segment; wherein the biimidazole guanidine organic tertiary phosphine chain segment has strong basicity and can efficiently catalyze the transesterification, and the functionalized phosphorylcholine chain segment is similar to L-alpha-choline alfoscerate in structure and can promote the solubility of organic base and increase the reaction activity at the initial stage of the reaction. The polymeric organic base disclosed by the invention can be used as an immobilized catalyst for preparing phosphatidylcholine compounds from fatty acid ester and L-alpha-choline alfoscerate through transesterification.

This invention relates to proliposomal powder dispersions of testosterone undecanoate (TU) and phospholipids, including dispersions of TU and palmitoylphosphatidylcholine (DPPC), wherein the weight / weight (w / w) ratio of TU:DPPC in the proliposomal powder dispersion is about 1:2; or TU and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), wherein the weight / weight (w / w) ratio of TU:DMPC in the proliposomal powder dispersion is about 1:3; or TU and a 1-myristoyl-2-palmitoyl-sn-glycero 3-phosphocholine (MPPC), wherein the weight / weight (w / w) ratio of TU:MPPC in the proliposomal powder dispersion is about 1:3.

The invention discloses a plugging device based on a plugging film with a surface microstructure and an anti-coagulation coating and a preparation method of the plugging device. The preparation method comprises the following steps: (1) designing and processing a metal template with a convex shape consistent with the appearance of the microstructure; meanwhile, the surface of the unstructured plugging film is treated, and an epoxy phosphorylcholine-containing polymer is grafted by introducing amino; (2) the obtained blocking film is placed on a heating table, the protruding morphology side of a metal template is attached to the blocking film, pressurization is conducted, meanwhile, heating is conducted through the heating table, and the metal template is rapidly soaked in ethyl alcohol to be cooled, fix patterns and dried after heating is completed; 3) preparing the plugging film obtained in the step 2) into a plugging device; according to the method, the microstructure and the coating are formed on the plugging film at the same time through one-step treatment, the preparation process of the corresponding plugging device structure is greatly simplified, repeatability is good, and the property is stable.

The object of the present invention is a liposomal composition comprising the tripeptide glycyl-L-histidyl-L-lysine-copper (GHK-Cu) complex, wherein said complex is encapsulated in lipid carrier A comprising 19 to 39 wt % of the sodium salt of 1,2-distearoyl-sn-glycero-3- phosphoglycerol (DSPG-Na), 29 to 42 wt % of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 24 to 41 wt % of cholesterol, or in lipid carrier B comprising 16 to 21 wt % of N- [carbonyl-methoxy(polyethylene glycol)-2000]-1,2-distearoyl-sn-glycero-3- phosphoethanolamine (DSPE-PEG2000), 48 to 63 wt % of hydrogenated soybean phosphatidylcholine (HSPC) and 16 to 36 wt % of cholesterol. A further object of the invention is a method for preparing the liposomal composition of the invention and its use as a component of a cosmetic formulation.

The invention discloses a saponin liposome immunologic adjuvant and a preparation method thereof, and belongs to the technical field of vaccine adjuvants. The preparation method comprises the following steps: firstly, preparing a blank liposome from 1, 2-dioleoyl-sn-glycerol-3-phosphorylcholine, cholesterol and DSPE-PEG-NHS, and then carrying out surface modification on the liposome by introducing a polyvinyl alcohol-protein graft polymer to form a stable core-shell structure; and finally, encapsulating the QS-21 in the liposome through active drug loading, and freeze-drying to obtain a final product. Through the synergistic effect of the DSPE-PEG-NHS and the polyvinyl alcohol-protein graft polymer, the structural integrity of the liposome in the freeze-drying and storage process is remarkably enhanced, hydrolysis and rearrangement of QS-21 are effectively inhibited, and the problem of chemical instability of QS-21 is solved. The obtained saponin liposome immunologic adjuvant has the advantages of high stability and strong immunogenicity.

The utility model discloses RO (Reverse Osmosis) membrane equipment of citicoline sodium, which relates to the technical field of citicoline sodium production and comprises a separation tank, the end part of the separation tank is fixedly connected with a mounting disc through a bolt, two fixing rings are arranged in the separation tank, the outer part of each fixing ring is in threaded connection with a threaded connection ring, and the threaded connection ring is in threaded connection with the separation tank. And an RO membrane is arranged in the separation tank, the two ends of the RO membrane are slidably connected with the two fixing rings correspondingly, and a collecting mechanism is arranged in the RO membrane. By arranging the fixing ring, the RO membrane and the collecting mechanism, a water system in the separation and purification stage in the citicoline sodium synthesis process can be treated, so that products discharged along with the water system are intercepted and recycled, the yield of the products is improved, meanwhile, the treatment difficulty of wastewater is also reduced, and the treatment cost is reduced. And the collection mechanism can be effectively utilized to complete automatic collection of citicoline sodium solids, and convenience is also brought to follow-up replacement of RO membranes by workers.

The application discloses a kind of phase change microcapsule-MXene-modified polyacrylate fabric coating and its preparation method and application, belong to fabric coating technical field, including the following steps: MXene dispersion liquid and phosphocholine modified polyacrylate emulsion are mixed, then octadecane polystyrene-polyaniline microcapsule dispersion liquid is added, mixed uniformly, to obtain composite coating slurry;Composite coating slurry is deposited on the surface of fabric using vacuum filtration process, and is dried to obtain phase change microcapsule-MXene-modified polyacrylate fabric coating.The fabric coating preparation method provided by the application is simple and efficient, and the coated fabric is applied in the field of intelligent wearable devices, which can simultaneously realize the multiple responses of conductivity, humidity and thermal management function, and has wide application value.

The present invention provides a pharmaceutical composition for the lubrication of joints, with the pharmaceutical composition including a non-ionic tonicity agent of a polyol such as mannitol, and liposomes having a membrane that includes at least a phospholipid selected from the group consisting of dimyristoylphosphatidylcholine (DMPC); a mixture of DMPC and dipalmitoyl-phosphatidylcholine (DPPC); a mixture of DMPC and 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); a mixture of DMPC and N-palmitoyl-D-erythro-sphingosy lphosphorylcholine (D-erythro C16); and a mixture of DMPC and 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine (C-15); wherein the pharmaceutical composition is essentially free of hyaluronic acid and any additional pharmaceutically active agents, wherein the at least one membrane has a phase transition temperature in the range of about 20° C. to about 39° C., and the joint has a joint temperature which is above the phase transition temperature.

The invention belongs to the field of inspection, and particularly relates to a composite marker for detecting biomarkers related to lysosomal storage diseases based on UPLC-MS / MS. The composite marker comprises a marker and an isotope internal standard substance, wherein the marker comprises glucosyl sphingosine, spherical glycosyl sphingosine, hemolytic sphingomyelin, N-palmitoyl-O-phosphorylcholine-serine, 7-ketocholesterol, cholestane-3, 5, 6-triol, galactosyl sphingosine, C26-ceramide, hemolytic GM1 ganglioside and hemolytic GM2 ganglioside, and the molecular weight of the marker is 8000-9000. The isotope internal standard substance is prepared from < 13 > C < 6 >-glucosyl sphingosine, D7-spherical glycosyl sphingosine, D9-lysosphingomyelin, D9-N-palmitoyl-O-phosphorylcholine-serine, D7-7-ketocholesterol, D7-cholestane-3, 5, 6-triol and D5-galactosyl sphingosine. The invention also comprises a UPLC-MS / MS method for detecting the composite marker. According to the invention, simultaneous detection of multiple biomarkers related to lysosomal storage diseases is realized, and the method is simple and convenient to operate, high in flux and low in cost.

The present disclosure provides a Lipid-Phosphocholine-Carboxylic Acid Agent being a compound comprising one or more groups, wherein each group is independently selected from Lipid Moiety (LM), Phosphocholine Moiety (PCM), Carboxylic Acid Moiety, Amide Moiety, and Attachment Moiety (AM), and wherein each group is covalently attached, directly or indirectly, to a multivalent linker (i.e., Composition Linker Moiety (CLM)), or pharmaceutically acceptable salts thereof, and related conjugates. The present disclosure also relates to uses of the Lipid-Phosphocholine-Carboxylic Acid Agents and conjugates, e.g., in delivering nucleic acid and / or treating or preventing diseases.

This invention provides a method for synthesizing zwitterionic copolymers, comprising the following steps: a betaine-based zwitterionic monomer and a 2-methacryloyloxyethyl phosphocholine (MPC) monomer are subjected to a free radical copolymerization reaction in a solvent to obtain the zwitterionic copolymer; wherein the betaine-based zwitterionic monomer is selected from carboxybetaine methacrylate (CBMA) monomer or sulfobetaine methacrylate (SBMA) monomer; the free radical copolymerization reaction is selected from reversible addition-fragmentation chain transfer (RAFT) polymerization or free radical polymerization (FRP); when the free radical copolymerization reaction is RAFT polymerization, the copolymerization reaction is carried out in the presence of both an initiator and a chain transfer agent (CTA); when the free radical copolymerization reaction is FRP, the copolymerization reaction is carried out in the presence of an initiator without the addition of a chain transfer agent. This invention can be widely applied in fields such as in vitro diagnostic sealing agents, and is a new generation of fully synthetic biomaterial solutions to replace animal-derived sealing agents and traditional PEG coatings.

The invention provides a quick response type nutrient composition for a cognitive load scene. The quick response type nutrient composition is prepared from the following raw materials in parts by weight: 400 to 600 parts of L-alpha-choline alfoscerate, 0.1 to 0.4 part of pyrroloquinoline quinone disodium salt, 4 to 6 parts of blueberry anthocyanin, 4 to 6 parts of gamma-aminobutyric acid, 4 to 6 parts of L-lysine and 4 to 6 parts of L-arginine. The invention further provides a preparation method and application of the quick response type nutrient composition for the cognitive load scene. Through the synergistic effect of the six components, a nerve cell energy metabolism-neurotransmitter balance-oxidation protection three-channel synergistic mechanism is formed, through the multi-target-point synergistic effect, the prepared nutrient composition has the multiple effects of improving the cognitive decline symptom, rapidly relieving cognitive fatigue, improving the thinking agility and reducing the error rate; the method is especially suitable for a high-intensity cognitive load scene. The invention belongs to the technical field of food processing.